Citadel Advisors
HZNP

Citadel Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Citadel Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-571,700
Closed -$66.1M – 15760
2023
Q3 		$66.1M Sell
571,700
-226,800
-28% -$24.4M 0.01% 878
2023
Q2 		$82.1M Buy
798,500
+776,000
+3,449% +$81.9M 0.02% 734
2023
Q1 		$2.46M Sell
22,500
-559,800
-96% -$61.9M ﹤0.01% 4993
2022
Q4 		$66.3M Buy
582,300
+410,300
+239% +$34.1M 0.02% 915
2022
Q3 		$10.6M Buy
172,000
+89,200
+108% +$6.23M ﹤0.01% 2669
2022
Q2 		$6.6M Sell
82,800
-53,000
-39% -$5.02M ﹤0.01% 3310
2022
Q1 		$14.3M Sell
135,800
-14,200
-9% -$1.38M ﹤0.01% 2429
2021
Q4 		$16.2M Sell
150,000
-50,200
-25% -$5.48M ﹤0.01% 2306
2021
Q3 		$21.9M Buy
200,200
+93,500
+88% +$9.71M ﹤0.01% 1887
2021
Q2 		$9.99M Sell
106,700
-111,400
-51% -$10.3M ﹤0.01% 3073
2021
Q1 		$20.1M Buy
218,100
+81,500
+60% +$6.88M ﹤0.01% 1959
2020
Q4 		$9.99M Buy
136,600
+9,900
+8% +$736K ﹤0.01% 2643
2020
Q3 		$9.84M Buy
126,700
+50,700
+67% +$3.49M ﹤0.01% 2314
2020
Q2 		$4.22M Buy
76,000
+5,900
+8% +$252K ﹤0.01% 3319
2020
Q1 		$2.08M Sell
70,100
-7,800
-10% -$264K ﹤0.01% 4087
2019
Q4 		$2.82M Buy
77,900
+25,500
+49% +$782K ﹤0.01% 3870
2019
Q3 		$1.43M Sell
52,400
-3,300
-6% -$85.3K ﹤0.01% 5010
2019
Q2 		$1.34M Sell
55,700
-70,100
-56% -$1.78M ﹤0.01% 5210
2019
Q1 		$3.33M Buy
125,800
+44,300
+54% +$1.05M ﹤0.01% 3585
2018
Q4 		$1.59M Sell
81,500
-82,500
-50% -$1.62M ﹤0.01% 4526
2018
Q3 		$3.21M Buy
164,000
+25,700
+19% +$489K ﹤0.01% 3619
2018
Q2 		$2.29M Buy
138,300
+42,000
+44% +$640K ﹤0.01% 3908
2018
Q1 		$1.37M Sell
96,300
-59,300
-38% -$876K ﹤0.01% 4324
2017
Q4 		$2.27M Buy
155,600
+53,400
+52% +$750K ﹤0.01% 3460
2017
Q3 		$1.3M Sell
102,200
-21,300
-17% -$271K ﹤0.01% 3956
2017
Q2 		$1.47M Buy
123,500
+30,800
+33% +$383K ﹤0.01% 3567
2017
Q1 		$1.37M Sell
92,700
-284,900
-75% -$4.61M ﹤0.01% 3549
2016
Q4 		$6.11M Buy
377,600
+184,200
+95% +$3.34M 0.01% 1786
2016
Q3 		$3.51M Buy
193,400
+42,700
+28% +$834K ﹤0.01% 2335
2016
Q2 		$2.48M Sell
150,700
-17,800
-11% -$288K ﹤0.01% 2508
2016
Q1 		$2.79M Sell
168,500
-14,900
-8% -$261K ﹤0.01% 2324
2015
Q4 		$3.97M Buy
183,400
+24,900
+16% +$485K ﹤0.01% 2025
2015
Q3 		$3.14M Buy
158,500
+52,900
+50% +$1.67M ﹤0.01% 2415
2015
Q2 		$3.67M Buy
105,600
+6,900
+7% +$211K ﹤0.01% 2366
2015
Q1 		$2.56M Buy
98,700
+12,100
+14% +$222K ﹤0.01% 2757
2014
Q4 		$1.12M Buy
86,600
+16,200
+23% +$203K ﹤0.01% 3640
2014
Q3 		$865K Buy
70,400
+37,100
+111% +$431K ﹤0.01% 3887
2014
Q2 		$527K Buy
33,300
+4,400
+15% +$62.8K ﹤0.01% 4315
2014
Q1 		$437K Buy
28,900
+18,400
+175% +$208K ﹤0.01% 4539
2013
Q4 		$80K Buy
10,500
+200
+2% +$1.08K ﹤0.01% 5775
2013
Q3 		$35K Sell
10,300
-6,300
-38% -$16.6K ﹤0.01% 5963
2013
Q2 		$41K Buy
+16,600
New +$39.8K ﹤0.01% 5764

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's HZNP Position: Q4 2023 in Review

Citadel Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,149,825 shares — an estimated $480M sold.

Citadel Advisors first reported a position in HZNP in Q2 2013 and held it in 41 quarters. The position peaked at $480M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Citadel Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 4,149,825 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $480M.
  • Citadel Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 41 quarters.
  • Citadel Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $480M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.